WuXi AppTec Co Ltd banner

WuXi AppTec Co Ltd
SSE:603259

Watchlist Manager
WuXi AppTec Co Ltd Logo
WuXi AppTec Co Ltd
SSE:603259
Watchlist
Price: 109.55 CNY -1.47% Market Closed
Market Cap: ¥326.9B

WuXi AppTec Co Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

WuXi AppTec Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
WuXi AppTec Co Ltd
SSE:603259
Pre-Tax Income
¥23.9B
CAGR 3-Years
31%
CAGR 5-Years
48%
CAGR 10-Years
N/A
J
Joinn Laboratories China Co Ltd
SSE:603127
Pre-Tax Income
¥337.5m
CAGR 3-Years
-35%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Pre-Tax Income
¥1.9B
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Pre-Tax Income
¥7.3B
CAGR 3-Years
11%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Pre-Tax Income
¥1.3B
CAGR 3-Years
-21%
CAGR 5-Years
-14%
CAGR 10-Years
19%
W
WuXi XDC Cayman Inc
HKEX:2268
Pre-Tax Income
¥1.7B
CAGR 3-Years
107%
CAGR 5-Years
122%
CAGR 10-Years
N/A
No Stocks Found

WuXi AppTec Co Ltd
Glance View

In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.

Intrinsic Value
102.33 CNY
Overvaluation 7%
Intrinsic Value
Price ¥109.55

See Also

What is WuXi AppTec Co Ltd's Pre-Tax Income?
Pre-Tax Income
23.9B CNY

Based on the financial report for Dec 31, 2025, WuXi AppTec Co Ltd's Pre-Tax Income amounts to 23.9B CNY.

What is WuXi AppTec Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
48%

Over the last year, the Pre-Tax Income growth was 107%. The average annual Pre-Tax Income growth rates for WuXi AppTec Co Ltd have been 31% over the past three years , 48% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett